116 related articles for article (PubMed ID: 35032770)
1. Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients.
Virseda-Berdices A; Rojo D; Martínez I; Berenguer J; González-García J; Brochado-Kith O; Fernández-Rodríguez A; Díez C; Hontañon V; Pérez-Latorre L; Micán R; Barbas C; Resino S; Jiménez-Sousa MA;
Biomed Pharmacother; 2022 Mar; 147():112623. PubMed ID: 35032770
[TBL] [Abstract][Full Text] [Related]
2. Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study.
Medrano LM; Berenguer J; Salgüero S; González-García J; Díez C; Hontañón V; Garcia-Broncano P; Ibañez-Samaniego L; Bellón JM; Jiménez-Sousa MA; Resino S
Front Med (Lausanne); 2021; 8():615342. PubMed ID: 33598470
[No Abstract] [Full Text] [Related]
3. Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients.
Salgüero S; Rojo D; Berenguer J; González-García J; Fernández-Rodríguez A; Brochado-Kith O; Díez C; Hontañon V; Virseda-Berdices A; Martínez J; Ibañez-Samaniego L; Llop-Herrera E; Barbas C; Resino S; Jiménez-Sousa MA;
Liver Int; 2020 Sep; 40(9):2215-2227. PubMed ID: 32593189
[TBL] [Abstract][Full Text] [Related]
4. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients.
Brochado-Kith Ó; Martínez I; Berenguer J; González-García J; Salgüero S; Sepúlveda-Crespo D; Díez C; Hontañón V; Ibañez-Samaniego L; Pérez-Latorre L; Fernández-Rodríguez A; Ángeles Jiménez-Sousa M; Resino S
Front Immunol; 2021; 12():723196. PubMed ID: 34497613
[TBL] [Abstract][Full Text] [Related]
5. Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis: a cross-sectional study.
Salgüero S; Medrano LM; González-García J; Berenguer J; Montes ML; Diéz C; Garcia-Broncano P; Llop-Herrera E; Pérez-Latorre L; Bellóno JM; Jiménez-Sousa MÁ; Resino S
Sci Rep; 2020 Jun; 10(1):10384. PubMed ID: 32587340
[TBL] [Abstract][Full Text] [Related]
6. Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection.
Macías J; Granados R; Téllez F; Merino D; Pérez M; Morano LE; Palacios R; Paniagua M; Frías M; Merchante N; Pineda JA;
J Viral Hepat; 2019 Jan; 26(1):16-24. PubMed ID: 30141222
[TBL] [Abstract][Full Text] [Related]
7. Rising Lysophosphatidylcholine Levels Post-Hepatitis C Clearance.
Peschel G; Krautbauer S; Weigand K; Grimm J; Höring M; Liebisch G; Müller M; Buechler C
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256273
[TBL] [Abstract][Full Text] [Related]
8. Urinary metabolomics of HCV patients with severe liver fibrosis before and during the sustained virologic response achieved by direct acting antiviral treatment.
Biliotti E; Giampaoli O; Sciubba F; Marini F; Tomassini A; Palazzo D; Capuani G; Esvan R; Spaziante M; Taliani G; Miccheli A
Biomed Pharmacother; 2021 Nov; 143():112217. PubMed ID: 34560544
[TBL] [Abstract][Full Text] [Related]
9. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.
Poveda E; Vispo E; Barreiro P; de Mendoza C; Labarga P; Fernández-Montero JV; Martin-Carbonero L; Soriano V
Antivir Ther; 2012; 17(3):571-5. PubMed ID: 22293607
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
[TBL] [Abstract][Full Text] [Related]
11. Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals.
Molina-Carrión S; Brochado-Kith Ó; González-García J; Berenguer J; Díez C; Llop E; Hontañón V; Ibañez-Samaniego L; Montes ML; Resino S; Fernández-Rodríguez A; Jiménez-Sousa MÁ
J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32731419
[TBL] [Abstract][Full Text] [Related]
12. DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV.
El-Garem H; AbdAllah M; Omar H; Cordie A; Abdel Alem S; Mohey Eldin Elzahry MA; Ghaith D; Abou El-Soud NH; Kamal W; Elsharkawy A; Esmat G
Expert Rev Gastroenterol Hepatol; 2019 Jul; 13(7):693-698. PubMed ID: 31043104
[No Abstract] [Full Text] [Related]
13. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
[TBL] [Abstract][Full Text] [Related]
14. Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters.
Ferreira J; Bicho M; Serejo F
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543737
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
16. Impact of HCV eradication with direct-acting antiviral agents on serum gamma globulin levels in HCV and HCV/HIV coinfected patients.
Milazzo L; van den Bogaart L; Sollima S; Oreni L; Lai A; Morena V; Bonazzetti C; Ridolfo Anna L; Antinori S
Eur J Intern Med; 2020 May; 75():50-54. PubMed ID: 31980330
[TBL] [Abstract][Full Text] [Related]
17. Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.
Attia D; Deterding K; Cornberg J; Gebel MJ; Cornberg M; Manns MP; Wedemeyer H; Potthoff A
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):67-74. PubMed ID: 30239347
[TBL] [Abstract][Full Text] [Related]
18. Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.
Huang R; Rao HY; Yang M; Gao YH; Wang J; Jin Q; Ma DL; Wei L
World J Gastroenterol; 2021 Feb; 27(5):404-415. PubMed ID: 33584072
[TBL] [Abstract][Full Text] [Related]
19. Liver Stiffness-Based Strategies Predict Absence of Variceal Bleeding in Cirrhotic Hepatitis C Virus-Infected Patients With and Without Human Immunodeficiency Virus Coinfection After Sustained Virological Response.
Corma-Gómez A; Macías J; Morano L; Rivero A; Téllez F; Ríos MJ; Santos M; Serrano M; Palacios R; Merino D; Real LM; De Los Santos I; Vera-Méndez FJ; Galindo MJ; Pineda JA;
Clin Infect Dis; 2021 Mar; 72(5):e96-e102. PubMed ID: 33211801
[TBL] [Abstract][Full Text] [Related]
20. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
ANRS CO13 HEPAVIH Cohort
AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
